Laboratoire Francais Du Fractionnement Et Des Biotechnologies
发明人:
Dominique Bourel,Sylvie Jorieux,Christophe de Romeuf,Philippe Klein,Christine Gaucher,Nicolas Bihoreau,Emmanuel Nony
申请号：
US14702143
公开号：
US09879089B2
申请日:
2015.05.01
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
